Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06268717 · ClinicalTrials.gov registry record · NA

GI Alpha-Gal Study

A NA study of Irritable Bowel Syndrome and Diarrhea, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06268717 is a NA study of Irritable Bowel Syndrome and Diarrhea that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 30 participants, below the 144-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06268717, a NA study of Irritable Bowel Syndrome and Diarrhea, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.

Interventions

  • OTHER Ground pork containing alpha-gal
  • OTHER Pork meat not containing alpha-gal

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-10-17
Est. Completion 2026-06-02
Phase NA

What the Registry Record Tells You About NCT06268717

The ClinicalTrials.gov registry entry for NCT06268717 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target (79% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Ground pork containing alpha-gal is the first listed.

NCT06268717 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06268717 about?

NCT06268717 is a clinical study titled "GI Alpha-Gal Study". This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.

What is the current status of trial NCT06268717?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-10-17. Estimated completion is 2026-06-02.

What conditions does trial NCT06268717 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome, Diarrhea, Abdominal Pain, Vomiting, Alpha-Gal Syndrome.

What interventions are being tested in trial NCT06268717?

The interventions under investigation include: Ground pork containing alpha-gal (OTHER), Pork meat not containing alpha-gal (OTHER).

Who is sponsoring clinical trial NCT06268717?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06268717 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Irritable Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.